CUMBERLAND, R.I.--(BUSINESS WIRE)--Onset Therapeutics, a specialty pharmaceutical company focused on dermatology, today announced that positive data on the reduction of the acne-causing bacteria Propionibacterium acnes with BenzEFoam™ (benzoyl peroxide) 5.3% Emollient Foam was presented at a poster session during the Fall Clinical Dermatology Conference in Las Vegas, October 15 – 18th. The results were from an investigator-initiated study by James J. Leyden, MD, Emeritus Professor of Dermatology at the University of Pennsylvania School of Medicine, assessing BenzEFoam™ Emollient Foam, the first prescription foam formulation of benzoyl peroxide, and a commercially available benzoyl peroxide 8% wash in patients with P. acnes colonization on their backs.
